Mode
Text Size
Log in / Sign up
Phase 4 N=128 Randomized Double-blind Prevention

Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria

Oral Bacteria Levels in the Mouth

Enrolled (actual)
128
Serious AEs
0.0%
Results posted
Apr 2016
Primary outcome: Primary: Anaerobic Bacteria — 8.40; 8.42; 8.43 colony forming units — p=>0.05

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Total Flavor option 1 (Drug); Total Flavor option 2 (Drug); Placebo toothpaste: Crest Cavity Protection toothpaste (Drug)
Age
Adult · 22+ yrs
Sex
All
Sponsor
Colgate Palmolive
Primary completion
Mar 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Anaerobic Bacteria
7.68; 7.71; 8.37 <0.001 sig
PRIMARY
Anaerobic Bacteria
7.68; 7.71; 8.37 <0.001 sig
PRIMARY
Malodor Bacteria (Breath Odor Causing Bacteria)
5.99; 5.92; 6.32 0.002 sig
PRIMARY
Malodor Bacteria (Breath Odor Causing Bacteria)
5.99; 5.92; 6.32 0.002 sig

Summary

The primary objective was to evaluate the antibacterial effects of two toothpastes containing 0.3% triclosan, 2% copolymer and 0.234% sodium fluoride in a silica base as compared to a control regular fluoride toothpaste on anaerobic and malodor bacteria 12 hours after 13 days of product use. A secondary objective was to demonstrate that a toothpaste containing 0.3% triclosan, 2% copolymer, 0.234% sodium fluoride and a flavor with odor-masking ingredients in silica base (Colgate Total Toothpaste-Flavor Option 1) provides a level of antibacterial efficacy that is "equivalent" to a toothpaste containing 0.3% triclosan, 2% copolymer, 0.234% sodium fluoride and a regular flavor in silica base (Colgate Total Toothpaste-Flavor Option 2) after 13 days of product use.

Eligibility Criteria

Inclusion Criteria

  • Males and females in good general health aged 18 to 70 years.
  • A willingness to read, understand, and sign the Informed Consent Form after the nature of the study has been fully explained to them. Subject should demonstrate a willingness to comply with all study procedures and sampling schedules.
  • A minimum of 20 natural teeth with facial and lingual scorable surfaces.
  • Adequate oral hygiene and no signs of oral neglect.
  • Good periodontal health. Enrolled subjects will have no more than five periodontal pockets of 5 mm.
  • Subjects with gingival index greater than or equal to 1.0 (Loe-Silness Index) and plaque index greater than or equal to 1.5 (Turesky modification of Quigley-Hein Index) will be enrolled.

Exclusion Criteria

  • History of significant adverse effects following use of oral hygiene products such as toothpastes and mouthrinses. Allergy to personal care/consumer products or their ingredients.
  • Teeth that are grossly carious, fully crowned or extensively restored on facial and/or lingual surfaces, orthodontically banded, abutments, or third molars
  • History of diabetes or hepatic or renal disease, or other serious medical conditions or transmittable diseases, e.g. heart disease or AIDS.
  • History of rheumatic fever, heart murmur, mitral valve prolapse or other conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures.
  • Subjects on antibiotic, anti-inflammatory or anticoagulant therapy during the month preceding the baseline exam.
  • Significant oral soft tissue pathology, systemically related gingival enlargement, severe gingivitis (based on a visual examinations).
  • History of active severe periodontal disease with bleeding gums and loose teeth.
  • Gross dental caries, severe generalized cervical abrasion and/or enamel abrasion, large fractured or temporary restorations (based on visual examinations).will not be included in the tooth count.
  • Fixed or removable orthodontic appliance or removable partial dentures.
  • Participation in a dental plaque/gingivitis clinical study involving oral care products, within the last 30 days. History of dental prophylaxis or treatments in the past month.
  • Self reported pregnancy or lactation.
  • History or current use of objects to pierce the lips or tongue.
  • Subjects known to be an alcoholic, or a recovering alcoholic.
  • History or current use of recreational drugs.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02194621). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search